Abalone Peptide Analogue Design for Broad Antimicrobial Activity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antimicrobial peptides derived from abalone, such as hdMolluscidin, have limited commercial viability due to their length and activity scope, requiring the development of shorter analogues with enhanced antimicrobial activity against a broader range of bacteria and fungi.
Innovation Solution
Designing an antimicrobial peptide analogue with a hydrophobic group containing 1-3 amino acid residues and a hydrophilic group with 1 or 2 lysine residues, forming an α-helix structure, and modifying the C-terminal and N-terminal with amidation, methylation, acetylation, or palmitoylation to enhance activity and stability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If hdMolluscidin (46 amino acids) is used as the antimicrobial peptide, then strong antimicrobial activity against Gram positive and Gram negative bacteria is achieved, but the peptide length is too long for commercial viability and production efficiency
Solution Approach 1:
The patent divides the original 46-amino acid hdMolluscidin into smaller fragment peptides of 8-15 amino acids. This segmentation maintains the essential antimicrobial functional domains while removing excessive length, enabling commercial viability and improved production efficiency while retaining activity against Gram-positive and Gram-negative bacteria
Solution Approach 2:
The patent extracts the critical antimicrobial functional regions from the full-length hdMolluscidin sequence. By identifying and isolating the essential amino acid motifs responsible for membrane interaction and antimicrobial activity, the invention creates shortened peptides that preserve therapeutic efficacy without the burden of the complete 46-amino acid structure
2Reliability
If hdMolluscidin is used as the antimicrobial peptide, then antimicrobial activity is achieved, but activity against C. albicans is lacking
Solution Approach 1:
The patent modifies specific local regions of the peptide sequence to enhance antifungal activity. By altering amino acid residues at key positions (such as introducing aromatic or basic amino acids that interact with fungal cell membranes), the shortened peptides gain expanded spectrum activity against C. albicans while maintaining their original antibacterial efficacy
Solution Approach 2:
The patent systematically varies peptide parameters including amino acid composition, charge distribution, and hydrophobicity to broaden spectrum activity. By optimizing these parameters in the shortened peptide framework, the invention achieves enhanced versatility against both bacteria and fungi, overcoming the limitation of the original hdMolluscidin
3Productivity
If the peptide is shortened to 8-15 amino acids for commercial viability, then production efficiency and commercial applicability are improved, but antimicrobial activity may be reduced
Solution Approach 1:
The patent segments the full-length peptide into optimized fragments of 8-15 amino acids that correspond to functionally active regions. This segmentation reduces production complexity and cost while preserving the core antimicrobial mechanism, thereby maintaining therapeutic efficacy despite the shortened length
Solution Approach 2:
The patent optimizes critical peptide parameters including amino acid sequence composition, net charge, hydrophobicity ratio, and secondary structure propensity to maximize antimicrobial activity within the constrained 8-15 amino acid framework. These parameter optimizations ensure that the shortened peptides achieve potency comparable to or exceeding the full-length parent peptide
Data Source
AI summary
The present disclosure relates to an antimicrobial peptide analog derived from abalone and an antimicrobial pharmaceutical composition containing the same. The antimicrobial peptide analog according to the present disclosure is designed based on hdMolluscidin which is a peptide derived from the gill of abalone and has been designed to be commercially viable by reducing the number of amino acids. Despite the reduced number of amino acids, the designed peptide analog exhibits very superior antimicrobial activity as well as high membrane permeability and low hemolytic activity.